TM-38837 explained

TM-38837 is a small molecule inverse agonist/antagonist of the CB₁ cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.^[1] The company has announced phase I clinical trials.

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB₁ receptor antagonists such as rimonabant.^[2]

See also

• AM-6545

External links

• Experimental obesity drug avoids brain effects that troubled predecessors, press release

Notes and References

1. Web site: 7TM Pharma. January 18, 2011 . dead . https://web.archive.org/web/20110707065905/http://www.7tm.com/ . July 7, 2011 .
2. Hung MS, Chang CP, Li TC, Yeh TK, Song JS, Lin Y, Wu CH, Kuo PC, Amancha PK, Wong YC, Hsiao WC, Chao YS, Shia KS . 6 . Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist . ChemMedChem . 5 . 9 . 1439–43 . September 2010 . 20652930 . 10.1002/cmdc.201000246 . 34244587 . free .